| Drug Name: | Ranibizumab |
|---|
| Drug Class: | Anti-VEGF (vascular endothelial growth factor) monoclonal antibody |
|---|
| Mechanism of Action: | - Binds to and inhibits VEGF-A, a protein that promotes angiogenesis and vascular permeability
- Reduces abnormal blood vessel growth and leakage in the eye
|
|---|
| Use: | - Treatment of neovascular (wet) age-related macular degeneration
- Treatment of macular edema following retinal vein occlusion
- Treatment of diabetic macular edema
- Treatment of diabetic retinopathy
|
|---|
| Side Effects: | - Eye pain
- Blurred vision
- Increased intraocular pressure
- Conjunctival hemorrhage
- Eye redness
- Eye irritation
- Headache
- Nausea
|
|---|
| Contraindications: | - Hypersensitivity to ranibizumab or any component of the formulation
- Active or suspected ocular or periocular infection
- Uncontrolled glaucoma
|
|---|
| Specialty: | |
|---|